COMP <GO>
BBOT vs PRQR // REVENUE GROWTH (YOY)
BridgeBio Oncology Therapeutics Inc. (NASDAQ) VS. ProQR Therapeutics N.V. (NASDAQ) • 15-METRIC TALLY: BBOT 0
— PRQR 2
■ METRIC PARITY
LAST: $2.31 (-11.83%) • MKT CAP: $185.2M
revenue-growth
—
LAST: $1.32 (-5.04%) • MKT CAP: $186.3M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBOT VS. PRQR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BBOT | PRQR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 20.0 | 36.6 | -16.60 | PRQR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $185.2M | $186.3M | -$1.1M | PRQR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BBOT REV | PRQR REV | BBOT GROSS % | PRQR GROSS % | BBOT FCF | PRQR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $408.3M | — | — | — | -$114.5M | — |
| FY 2024 | $226.4M | — | — | — | -$55.1M | — |
| FY 2023 | $116.7K | — | — | — | — | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBOT // BETA —
PRQR // BETA —